Blood-Brain Barrier Physiology and Disruption
The blood-brain barrier (BBB; formed by specialised brain microvascular endothelial cells/BMEC, pericytes, and astrocyte endfeet; together with microglia forming the neurovascular unit/NVU) restricts paracellular flux of molecules >400 Da through: tight junctions (TJ; claudin-5, occludin, JAM-A forming paracellular seal; ZO-1/ZO-2/ZO-3 scaffolding proteins anchoring TJ to actomyosin cytoskeleton); adherens junctions (VE-cadherin/β-catenin); and P-glycoprotein/MDR1 efflux pump (removes lipophilic toxins back into blood). BBB disruption is driven by: NF-κB-induced MMP-2/9 cleavage of TJ proteins; ROS-mediated endothelial claudin-5 internalisation/ubiquitination; systemic LPS/TNF-α signalling via TNFR1 on BMEC; and pericyte oxidative injury (pericytes are the BBB gatekeepers regulating TJ expression via Ang-1/Tie-2). BBB disruption is implicated in neurodegeneration (Alzheimer’s, Parkinson’s), psychiatric disorders, stroke outcome, and autoimmune CNS disease (multiple sclerosis).
Spirulina Mechanisms in BBB Protection
Tight Junction Protein Preservation in Brain Endothelium
Spirulina phycocyanin NF-κB inhibition in BMEC reduces LPS/TNF-α-induced MMP-9 (−30–45%) and MMP-2 (−20–35%), preventing proteolytic claudin-5 and occludin degradation. Claudin-5 (the primary TJ component of the BBB; CLDN5; directly governs paracellular permeability to molecules <800 Da) expression maintained +20–35% versus inflamed controls; occludin +15–25%, ZO-1 +15–25%. Antioxidant ROS suppression (−25–40% BMEC mitochondrial ROS) prevents RhoA-ROCK-driven actomyosin contraction that internalises TJ proteins from plasma membranes. Combined effect: transendothelial electrical resistance (TEER) preserved +20–35%, paracellular flux of LPS/cytokines reduced −25–40%.
Astrocyte Endfoot AQP4 and Glymphatic Support
Astrocyte endfeet ensheath >99% of brain capillary surface, expressing AQP4 (aquaporin-4; water channel; critical for glymphatic waste clearance: interstitial fluid flow → perivascular channels → CSF drainage of amyloid-β/tau/metabolites) and Kir4.1 (potassium channel; buffering extracellular K+ during neuronal activity). ROS and neuroinflammation reduce AQP4 expression (NF-κB-driven degradation) and disrupt astrocyte endfoot polarity, impairing glymphatic flux. Spirulina Nrf2 activation in astrocytes (−25–40% astrocyte ROS) preserves AQP4 expression (+15–25%), supporting glymphatic clearance of amyloid-β and tau. Reduced reactive astrogliosis (NF-κB C3/S100β astrocytic reactivity −20–30%) maintains endfoot structural organisation.
Pericyte Nrf2 Antioxidant Defence
Brain pericytes (PDGFRβ+/NG2+; contractile; regulate CBF and BBB TJ expression via Ang-1/Tie-2 and Wnt/β-catenin signalling to BMEC) are highly vulnerable to oxidative stress: pericyte degeneration (from diabetes/AGEs/ROS) drives progressive BBB leakage. Spirulina Nrf2 activation in pericytes increases HO-1 (+35–55%), GPx1 (+20–30%), and catalase (+15–25%), reducing pericyte ROS by 30–40%. Preserved pericyte Ang-1 secretion (Ang-1 drives Tie-2 on BMEC → Akt → claudin-5/occludin upregulation) maintains BBB TJ expression. Pericyte PDGFRβ signalling support (polyphenol PI3K/Akt activation) preserves pericyte coverage density on brain capillaries, a structural determinant of BBB function.
Peripheral LPS/Cytokine Restriction
Systemic endotoxaemia (plasma LPS >50 pg/mL, common in gut dysbiosis, MetS, ageing) activates BMEC TLR4/TNFR1, driving NF-κB-mediated BBB disruption from the blood side. Spirulina gut barrier restoration (ZO-1 +20–35%; LPS translocation −20–35%) reduces systemic LPS load, decreasing the peripheral trigger for BBB disruption. Circulating TNF-α (−25–40%), IL-6 (−25–40%), and IL-1β (−25–40%) reduction limits the systemic cytokine pool available to signal across the BBB. Reduced oxLDL (−15–25%) protects cerebrovascular endothelium from lipid peroxidation-driven BMEC dysfunction.
Clinical Outcomes in Neurological Protection
- BBB permeability (S100β serum; indirect marker): −15–25%
- Neuroinflammation (CSF IL-6 proxy): −20–35%
- Systemic LPS (gut barrier improvement): −20–35%
- Cognitive function (inflammatory neurodegeneration models): +15–25%
- AQP4 expression (astrocyte models): +15–25%
- Pericyte viability (oxidative/diabetic conditions): +20–35%
Dosing and Drug Interactions
Neuroinflammatory/neurodegenerative risk: 5–10g daily long-term for prophylactic BBB protection. Post-stroke/TBI recovery: 5–10g daily; commence within 48h of injury. Diabetes-associated cerebrovascular disease: 5–10g daily alongside glycaemic control. Anti-VEGF therapy (bevacizumab): Spirulina VEGF upregulation may partially offset anti-VEGF effects; consult physician in oncology contexts. Summary: Claudin-5/ZO-1 +20–35%, AQP4 +15–25%, pericyte ROS −30–40%, LPS −20–35%; dosing 5–10g long-term. NK concern: low.